高危慢性淋巴细胞白血病靶向治疗后行异基因造血干细胞移植
该研究纳入108例2010至2018年接受异基因造血干细胞移植的高危慢性淋巴细胞白血病患者,其中30例移植前接受靶向治疗。靶向治疗组3年总生存率和无进展生存率分别为87%和69%,非复发死亡和复发累积发生率分别为7%和24%。移植前接受靶向治疗者早期循环T/B细胞数更高,CD4调节性T细胞与常规T细胞比值更低。
要点
- 靶向治疗后移植的高危CLL患者3年OS达87%、PFS达69%。
- 靶向治疗组3年非复发死亡累积发生率7%,复发累积发生率24%。
- 疾病控制下应尽早推荐alloHCT,不应因高危特征而延迟。
核心结论
- 尽管高危特征多,移植前接受靶向治疗的CLL患者临床结局优异,疾病控制时应推荐alloHCT。
研究设计与样本
- 回顾性研究纳入108例2010至2018年接受alloHCT的高危CLL患者,其中30例于2013至2018年移植前接受靶向治疗。
主要发现
- 靶向治疗组中位年龄60岁(范围30-71岁),完全缓解20%、部分缓解73%。
- 靶向治疗组76%有del(17p),46.2%有5个及以上细胞遗传学异常,78.9%为IGHV未突变。
- 靶向治疗组既往治疗中位数为4(范围1-9)。
- 中位随访36个月(范围10-72个月),靶向治疗组3年OS 87%、PFS 69%,非复发死亡累积发生率7%、复发累积发生率24%。
- 对照组78例2010至2014年移植前仅接受化学免疫治疗,3年OS 69%、PFS 58%。
关键数值与推荐
- 靶向治疗组移植后早期循环T和B细胞数显著更高,CD4调节性T细胞与CD4常规T细胞比值更低。
临床怎么用
- 高危CLL患者在靶向治疗使疾病得到控制后,应考虑行alloHCT。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Allogeneic hematopoietic cell transplantation (alloHCT) can cure previously treated high-risk chronic lymphocytic leukemia (CLL) patients if they are suitable for transplant through the graft-versus-leukemia effect. However, since the emergence of targeted therapies, the role of alloHCT for high-risk CLL is less clear. To address this question, we evaluated 108 high-risk CLL patients who underwent alloHCT from 2010 to 2018. Thirty patients from the period of 2013 to 2018 received targeted therapy prior to alloHCT. The median age for the targeted therapy cohort was 60 years (range, 30-71 years), and 20% and 73% had complete and partial remission, respectively: 76% had del(17p), 46.2% had 5 or more cytogenetic abnormalities, and 78.9% were IGHV unmutated. The median number of prior therapies was 4 (range, 1-9). With a median follow-up time of 36 months (range, 10-72 months), the 3-year overall (OS) and progression-free survival (PFS) were 87% and 69%, respectively. The 3-year cumulative incidence of nonrelapse mortality and relapse was 7% and 24%, respectively. For the control cohort of 78 patients who underwent alloHCT from 2010 to 2014 and received only chemoimmunotherapy prior to transplant, the 3-year OS and PFS were 69% and 58%, respectively. Patients treated with targeted therapy prior to alloHCT had a significantly higher number of circulating T and B cells and a lower ratio of CD4 regulatory T cells to CD4 conventional T cells early after transplant. In summary, despite multiple high-risk features, the clinical outcome of CLL patients who receive targeted therapy prior to transplant is excellent and alloHCT should be offered while the disease is under control.
引用
- Kim HT, Shaughnessy CJ, Rai SC, et al. Allogeneic hematopoietic cell transplantation after prior targeted therapy for high-risk chronic lymphocytic leukemia. Blood Adv. 2020. PMID: 32882002. doi:10.1182/bloodadvances.2020002184
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。